LIN28A: Key Regulator of Cell-Cell Adhesion and Potential Drug Target

Target Name: LIN28A

NCBI ID: G79727

LIN28A

LIN28A: Key Regulator of Cell-Cell Adhesion and Potential Drug Target

LIN28A, also known as LIN28, is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell-cell adhesion, which is a process that helps maintain tissue structure and function. LIN28A has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, LIN28A has become a focus of interest for researchers as a potential drug target or biomarker.

Disease-Related Function

LIN28A has been shown to be involved in the development and progression of several diseases, including cancer. For example, studies have shown that LIN28A is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, LIN28A has been shown to play a role in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.

In addition to its involvement in disease-related functions, LIN28A has also been shown to have potential as a drug target. LIN28A has been shown to interact with several protein targets, including the transcription factor NF-kappa-B. This suggests that LIN28A may be a useful target for drugs that are designed to inhibit the activity of NF-kappa-B, which is a known regulator of inflammation and cancer.

Antibodies as a Tool for Research

Antibodies are a powerful tool for research in LIN28A and its role in disease. Antibodies are proteins that are produced by the immune system in response to the presence of a specific antigen. They can be used to detect and quantify the presence of LIN28A in various tissues and cells, and can also be used to study its interactions with other proteins.

One of the advantages of using antibodies for research is that they can be used to detect LIN28A in a variety of samples, including biological fluids, tissues, and cells. This makes them an ideal tool for studying the effects of drugs on LIN28A expression and function.

Another advantage of antibodies is that they can be used to study LIN28A interactions with other proteins. This can be important for understanding how LIN28A functions in different biological processes and for identifying potential drug targets.

Targeted Therapies

The potential of LIN28A as a drug target has led to the development of several targeted therapies that are currently in clinical trials. For example, a company called Oncocyte has developed a drug called OXY-00820 that is designed to inhibit LIN28A. OXY-00820 is being studied for its potential to treat various types of cancer, including breast, ovarian, and prostate cancer.

Another drug that is being developed to target LIN28A is a small molecule called LIN28R-ASP, which is being developed by the company Ligand Institute. LIN28R-ASP is designed to bind to a specific epitope on the LIN28A protein that is involved in its function as a cell adhesion regulator.

Conclusion

LIN28A is a protein that has been shown to be involved in the development and progression of several diseases, including cancer. As a result, LIN28A has become a focus of interest for researchers as a potential drug target or biomarker. Antibodies are a powerful tool for research in LIN28A, and targeted therapies are currently being developed to target LIN28A in order to treat various types of diseases. Further research is needed to fully understand the role of LIN28A in disease and to develop effective therapies.

Protein Name: Lin-28 Homolog A

Functions: RNA-binding protein that inhibits processing of pre-let-7 miRNAs and regulates translation of mRNAs that control developmental timing, pluripotency and metabolism (PubMed:21247876). Seems to recognize a common structural G-quartet (G4) feature in its miRNA and mRNA targets (Probable). 'Translational enhancer' that drives specific mRNAs to polysomes and increases the efficiency of protein synthesis. Its association with the translational machinery and target mRNAs results in an increased number of initiation events per molecule of mRNA and, indirectly, in mRNA stabilization. Binds IGF2 mRNA, MYOD1 mRNA, ARBP/36B4 ribosomal protein mRNA and its own mRNA. Essential for skeletal muscle differentiation program through the translational up-regulation of IGF2 expression. Suppressor of microRNA (miRNA) biogenesis, including that of let-7, miR107, miR-143 and miR-200c. Specifically binds the miRNA precursors (pre-miRNAs), recognizing an 5'-GGAG-3' motif found in pre-miRNA terminal loop, and recruits TUT4 and TUT7 uridylyltransferases (PubMed:18951094, PubMed:19703396, PubMed:22118463, PubMed:22898984). This results in the terminal uridylation of target pre-miRNAs (PubMed:18951094, PubMed:19703396, PubMed:22118463, PubMed:22898984). Uridylated pre-miRNAs fail to be processed by Dicer and undergo degradation. The repression of let-7 expression is required for normal development and contributes to maintain the pluripotent state by preventing let-7-mediated differentiation of embryonic stem cells (PubMed:18951094, PubMed:19703396, PubMed:22118463, PubMed:22898984). Localized to the periendoplasmic reticulum area, binds to a large number of spliced mRNAs and inhibits the translation of mRNAs destined for the ER, reducing the synthesis of transmembrane proteins, ER or Golgi lumen proteins, and secretory proteins. Binds to and enhances the translation of mRNAs for several metabolic enzymes, such as PFKP, PDHA1 or SDHA, increasing glycolysis and oxidative phosphorylation. Which, with the let-7 repression may enhance tissue repair in adult tissue (By similarity)

The "LIN28A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LIN28A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets